Is Shed Legit? What Their 10% Weight Loss Guarantee Actually Means

Shed (operating at shed.com, also known as tryshed.com and shedrx) is a telehealth company founded in 2023 and headquartered in Lehi, Utah. The company focuses exclusively on GLP-1 weight loss treatments, distinguishing itself from broader telehealth platforms that spread across dozens of therapeutic areas. With over 150,000 members nationwide as of early 2026, Shed has scaled rapidly in the competitive GLP-1 telehealth market. Their singular focus on weight management allows them to build deeper clinical protocols and patient support systems than general-purpose competitors.

Shed operates as a legitimate business entity registered in Utah, with a verifiable physical presence in Lehi - a hub for technology and healthcare startups along Utah's Silicon Slopes corridor. The company maintains an active profile on the Better Business Bureau and can be verified through Utah state business registrations. Unlike some telehealth startups that operate through shell entities or offshore structures, Shed's corporate transparency is straightforward and verifiable through standard business lookup tools.

The company has accumulated over 7,500 patient reviews with an average rating of 4.6 out of 5 stars, which can be independently verified through platforms like Trustpilot and Google Reviews. This volume of reviews provides a statistically meaningful sample size for evaluating patient satisfaction - far exceeding the minimum threshold most consumer research organizations consider reliable. The consistency of the rating across thousands of reviews suggests genuine patient experiences rather than manufactured testimonials.

One of Shed's most notable corporate commitments is their 10% weight loss money-back guarantee, which represents a significant financial bet on their own clinical outcomes. Companies that offer outcome-based guarantees must maintain strong internal tracking and quality assurance systems - a guarantee of this nature would be financially unsustainable without genuinely effective treatment protocols. This kind of accountability signal is relatively rare in the telehealth weight loss space and suggests confidence in their clinical model.

Shed's process begins with an online health assessment that collects your medical history, current medications, weight loss goals, and relevant health markers. This questionnaire is designed to screen for contraindications to GLP-1 medications, including a history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pancreatitis - all conditions the FDA flags as contraindications for semaglutide-based treatments. The assessment typically takes 10 to 15 minutes and can be completed from any device.

After submitting your assessment, a US-licensed physician reviews your information and determines whether GLP-1 therapy is appropriate for your clinical profile. This is not an automated approval system - each case receives individual physician evaluation as required by state medical board regulations. If approved, your prescriber selects the appropriate medication format and dosing schedule based on your health profile. Shed offers multiple GLP-1 formats including injectable semaglutide, sublingual drops, lozenges, and oral tablets, giving physicians flexibility to match the delivery method to patient preferences and clinical needs.

Once prescribed, your medication is dispensed through licensed US compounding pharmacies that operate under FDA compounding guidelines and state pharmacy board oversight. Medications ship directly to your door in temperature-controlled packaging when required for injectable formulations. Shed also offers brand-name options including Wegovy and Zepbound for patients who prefer FDA-approved branded medications over compounded alternatives, making them one of the few telehealth platforms offering both pathways.

Ongoing care includes regular check-ins with your prescribing physician, dose adjustments as needed, and access to Shed's support team. The company's 10% weight loss guarantee means your care team is incentivized to optimize your protocol rather than simply maintain a subscription. Patients who do not achieve at least 10% body weight loss within the guarantee period can receive a refund, which creates an alignment of incentives between the company and its patients that is uncommon in subscription-based telehealth.

Shed's treatment model aligns with clinical evidence showing that GLP-1 receptor agonists like semaglutide produce average weight loss of 15 to 20% of body weight over 68 weeks, as demonstrated in the landmark STEP 1 trial published in the New England Journal of Medicine. By offering multiple medication formats, Shed can accommodate patients who may have difficulty with self-injection, potentially improving long-term adherence to treatment protocols.

All prescriptions through Shed are written by US-licensed physicians who hold active medical licenses in the states where they practice. This is a non-negotiable requirement under Federation of State Medical Boards (FSMB) guidelines, which mandate that physicians must be licensed in the state where the patient is located at the time of the telehealth consultation. Shed's compliance with these regulations means every prescribing physician can be independently verified through state medical board databases.

You can verify any physician's credentials through the American Board of Medical Specialties (ABMS) verification service or your state's medical board online lookup tool. These public databases show a physician's license status, board certifications, any disciplinary actions, and education history. Legitimate telehealth platforms like Shed should have no issue with patients independently verifying their prescribers - and this verification step is something we recommend for any online healthcare service.

The telehealth consultation model Shed uses has been validated by extensive regulatory evolution since 2020, when the DEA and state medical boards expanded telehealth prescribing authority. For weight management medications like GLP-1 agonists, asynchronous telehealth consultations (where the physician reviews your records without a live video call) are permitted in most states, provided the consultation meets established standards of care. Shed's physician review process must meet these same standards regardless of whether the interaction is synchronous or asynchronous.

Shed's focus exclusively on GLP-1 weight loss means their physicians develop specialized expertise in this medication class rather than prescribing across dozens of therapeutic areas. This specialization model is consistent with best practices in medicine - physicians who focus on specific treatment areas tend to develop deeper pattern recognition for contraindications, side effect management, and dose optimization. The American Medical Association has recognized telehealth specialization as a legitimate and effective model for delivering focused care.

It is worth noting that Shed's 10% weight loss guarantee creates an additional layer of clinical accountability. Physicians prescribing through the platform have a direct outcome measure tied to their treatment decisions, which incentivizes careful patient selection and proactive dose management rather than a prescribe-and-forget approach that can plague some telehealth platforms.

It is important to distinguish between the FDA approval status of medications and the regulatory status of the telehealth platform itself. The FDA does not approve or regulate telehealth companies directly - it regulates medications and the pharmacies that dispense them. Shed offers both FDA-approved brand-name GLP-1 medications (Wegovy and Zepbound) and compounded semaglutide preparations, giving patients a choice between branded and compounded options based on availability, preference, and budget.

Brand-name medications like Wegovy (semaglutide) and Zepbound (tirzepatide) have undergone the full FDA approval process, including large-scale clinical trials demonstrating safety and efficacy. Wegovy was approved by the FDA in June 2021 based on the STEP clinical trial program, which enrolled over 4,500 participants and showed average weight loss of approximately 15% of body weight over 68 weeks (FDA approval announcement). Zepbound (tirzepatide) received FDA approval for weight management in November 2023.

Shed's compounded semaglutide is prepared by licensed US compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies compound medications based on individual prescriptions, while 503B outsourcing facilities can produce larger batches under more stringent FDA oversight including current Good Manufacturing Practice (cGMP) requirements. Both pathways are legal and regulated, though they involve different levels of federal oversight.

The availability of multiple GLP-1 formats through Shed - injections, sublingual drops, lozenges, and oral tablets - reflects the versatility of compounding pharmacies to prepare medications in alternative delivery systems. While injectable semaglutide has the most extensive clinical trial data, alternative delivery formats can improve patient adherence for those uncomfortable with self-injection. Each compounding pharmacy in Shed's network must maintain state pharmacy licensure and comply with United States Pharmacopeia (USP) standards for sterile and non-sterile compounding.

Shed's decision to offer both compounded and brand-name options is notable because it gives patients and physicians maximum flexibility. When brand-name supply is constrained (as has occurred periodically with both Wegovy and Zepbound), compounded alternatives ensure treatment continuity. When supply normalizes, patients can transition to brand-name formulations if preferred. This dual-pathway approach, combined with Shed's 10% weight loss guarantee, suggests the company prioritizes treatment outcomes over locking patients into a single medication source.

Shed has accumulated over 7,500 patient reviews with an average rating of 4.6 out of 5 stars, making it one of the more extensively reviewed telehealth weight loss platforms. This review volume can be cross-referenced on independent platforms including Trustpilot and Google Reviews, where third-party verification systems help filter fraudulent or incentivized reviews. A 4.6 rating at this volume is statistically significant - random variation alone cannot sustain a rating this high across thousands of independent data points.

Positive reviews commonly highlight several themes: the convenience of the online process, the variety of GLP-1 medication formats available, the responsiveness of the care team, and meaningful weight loss results. Patients frequently mention Shed's 10% weight loss guarantee as a factor in their initial decision to try the service, and many report exceeding that threshold. The availability of non-injection formats (sublingual drops, lozenges, and oral tablets) is frequently cited by patients who had previously avoided GLP-1 treatment due to needle aversion.

Critical reviews, which represent a minority but deserve attention, most commonly cite shipping delays, difficulty reaching customer support during peak demand periods, and side effects associated with GLP-1 medications themselves (nausea, constipation, and decreased appetite are commonly reported class effects). It is important to note that side effects mentioned in negative reviews are generally consistent with the known side effect profile of GLP-1 receptor agonists documented in clinical trials rather than quality issues specific to Shed.

When evaluating patient reviews for any telehealth service, we recommend looking for specific details rather than generic praise or complaints. Reviews that mention specific medication formats, dosing timelines, and measurable weight loss outcomes tend to be more reliable indicators of genuine patient experience. Shed's review corpus includes a high proportion of detailed, specific accounts, which increases confidence in the authenticity of the overall rating.

The 150,000-plus member count reported by Shed represents substantial real-world usage data. At this scale, systematic problems with medication quality, physician care, or business practices would generate visible patterns in public reviews and regulatory complaints. The absence of significant regulatory actions or widespread consumer complaints, combined with the sustained high review average, provides reasonable confidence in the platform's operational integrity.

Shed's 10% weight loss money-back guarantee is one of the most distinctive features in the telehealth weight loss market. The guarantee promises that if you do not lose at least 10% of your starting body weight within the specified program period, you can receive a refund. This is a bold commitment given that the company's revenue depends on subscription payments - essentially, Shed is betting its own revenue on delivering measurable clinical outcomes for each patient.

The 10% threshold is clinically meaningful, not arbitrary. The CDC and major medical organizations recognize that a 5 to 10% reduction in body weight produces significant health improvements including reduced risk of type 2 diabetes, improved cardiovascular markers, and decreased joint stress. By setting the guarantee at 10%, Shed is committing to outcomes at the upper end of what guidelines consider clinically significant weight loss - a target that is ambitious but achievable with GLP-1 therapy based on published trial data.

This guarantee creates a fundamentally different incentive structure compared to standard telehealth subscriptions. Without an outcome guarantee, a telehealth platform profits regardless of whether the patient achieves meaningful results - the subscription continues as long as the patient keeps paying. Shed's guarantee flips this dynamic: the company only retains full revenue from patients who achieve at least 10% weight loss. This alignment of financial incentives with clinical outcomes is a structural advantage that benefits patients.

From a practical standpoint, the guarantee means Shed must invest in strong progress tracking, proactive dose adjustments, and responsive clinical support. A patient trending below the 10% threshold represents potential refund liability, which incentivizes the care team to intervene early - adjusting medication type, format, or dosage rather than passively continuing an underperforming protocol. This creates a feedback loop where the guarantee drives better clinical care, which drives better outcomes, which reduces refund rates.

When comparing Shed to competitors, the 10% weight loss guarantee stands out because most telehealth weight loss platforms offer satisfaction guarantees (subjective) or money-back windows (time-limited, not outcome-based). Shed's guarantee is specifically tied to a measurable, objective clinical outcome. For consumers evaluating telehealth options, this type of outcome-based guarantee is one of the strongest signals that a company has confidence in its clinical model and is willing to accept financial risk to back that confidence.

Shed's plans range from $199 to $499 per month, with pricing that varies based on the specific GLP-1 medication format and whether you choose compounded or brand-name options. The lower end of the range typically corresponds to compounded formulations (sublingual drops, lozenges, or oral tablets), while the higher end includes brand-name medications like Wegovy or Zepbound, which carry significantly higher wholesale costs. This pricing structure is transparent and competitive within the telehealth GLP-1 market, where comparable services generally range from $150 to $600 per month.

The monthly fee at Shed is structured as an all-inclusive price that covers the telehealth consultation, physician evaluation, prescription, medication, and shipping. This bundled approach eliminates the surprise charges that can plague unbundled telehealth models, where patients might pay separately for the consultation, prescription, medication, and each follow-up visit. Before subscribing, confirm the exact inclusions for your specific plan, as pricing and bundled services can change.

Compared to the retail cost of brand-name GLP-1 medications without insurance, Shed's pricing represents significant savings. Wegovy's list price exceeds $1,300 per month, and Zepbound's list price is approximately $1,060 per month without insurance or manufacturer coupons. Even Shed's highest tier at $499 per month represents a 50 to 60% discount relative to retail pricing for brand-name options, while the compounded alternatives at the lower price points offer even greater savings for patients paying out of pocket.

Shed's 10% weight loss guarantee adds an implicit value layer to the pricing equation. If you do not achieve the guaranteed results, the refund mechanism effectively reduces your net cost. This outcome-based pricing model means the effective cost per pound lost can be calculated after the program concludes - a metric worth considering when comparing Shed's total value proposition against competitors who charge similar monthly rates but offer no outcome guarantees.

When evaluating cost, consider the total program duration needed to achieve your goals. Clinical trials for semaglutide show that weight loss typically continues for 12 to 16 months before plateauing, with the most rapid loss occurring in months 3 through 9 (STEP 1 trial data). Budget accordingly for at least 6 to 12 months of treatment to give the medication adequate time to produce meaningful results. Stopping GLP-1 therapy prematurely is the most common reason patients fail to achieve their weight loss goals.

Like most telehealth GLP-1 platforms, Shed primarily operates on a direct-pay model where patients pay the subscription fee out of pocket rather than billing insurance directly. This is common in the compounded medication space because most insurance plans do not cover compounded formulations of semaglutide - insurance coverage for GLP-1 medications is generally limited to FDA-approved brand-name versions prescribed through traditional healthcare channels.

However, Shed's plans may be eligible for reimbursement through Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA), which allow you to use pre-tax dollars for qualified medical expenses. GLP-1 weight loss medications prescribed by a licensed physician for a documented medical condition (such as obesity or overweight with comorbidities) generally qualify as eligible HSA/FSA expenses under IRS guidelines. Using pre-tax dollars effectively reduces your out-of-pocket cost by your marginal tax rate - typically 22 to 32% for most taxpayers.

For patients interested in brand-name options (Wegovy or Zepbound) through Shed, there may be pathways to submit claims to your insurance for the medication component, depending on your specific plan and coverage. Some insurance plans have begun covering GLP-1 medications for weight management following the expanded FDA indications and CMS coverage decisions. Check with both Shed's support team and your insurance provider to understand your specific coverage options before assuming you must pay entirely out of pocket.

It is worth noting that the economics of GLP-1 therapy extend beyond the monthly subscription cost. Obesity-related healthcare costs average over $1,800 per year more than costs for individuals at healthy weight, according to CDC data. Achieving and maintaining clinically significant weight loss through a program like Shed can reduce long-term healthcare expenditures, prescription medication needs for comorbid conditions, and associated costs. The 10% weight loss guarantee further de-risks this investment by ensuring you receive measurable results or get your money back.

Shed operates on a subscription model, and understanding the cancellation terms before enrolling is important for any recurring payment commitment. Patients can typically cancel their subscription through their account dashboard or by contacting Shed's support team. As with any subscription service, review the specific terms of service at the time of enrollment, as policies can evolve and the most current terms will govern your account.

The 10% weight loss guarantee functions as Shed's primary refund mechanism and is the most consumer-friendly aspect of their financial terms. If you complete the program requirements and do not achieve at least 10% body weight loss, you are eligible for a refund under the guarantee terms. This outcome-based refund policy is substantially more protective than the standard 30-day satisfaction guarantees offered by most telehealth competitors, because it ties the refund to a measurable clinical result rather than an arbitrary time window.

When considering cancellation timing, keep in mind that GLP-1 medications require consistent use over months to achieve optimal results. The clinical evidence shows that semaglutide's weight loss effects are progressive, with the most significant results appearing after 3 to 6 months of continuous treatment. Canceling after just one or two months may not give the medication sufficient time to produce meaningful results, and premature discontinuation is the most common reason patients report dissatisfaction with GLP-1 programs across all platforms.

If you experience side effects that make continuing treatment untenable, communicate with your Shed physician before canceling. GLP-1 side effects like nausea are most common during the dose-escalation phase and often resolve with slower titration, temporary dose reduction, or switching between medication formats. Shed's multiple format options (injections, sublingual, lozenges, tablets) provide flexibility that many competitors lack - switching from injectable to sublingual delivery, for example, may resolve injection-site issues while maintaining therapeutic benefit.

Before enrolling, document the specific guarantee terms, cancellation process, and any minimum commitment periods. Screenshot or save the terms of service page, and keep confirmation emails for your records. This is standard consumer protection advice for any subscription healthcare service and ensures you have clear documentation if you need to exercise the cancellation or guarantee provisions later.

GLP-1 receptor agonist side effects are a medication class issue, not a Shed-specific issue, and understanding this distinction is critical for evaluating any GLP-1 telehealth provider. The most commonly reported side effects of semaglutide and tirzepatide include nausea (affecting approximately 44% of patients in clinical trials), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%), according to data from the STEP 1 clinical trial and the FDA prescribing information.

These gastrointestinal side effects are most prevalent during the dose-escalation phase, when the body is adjusting to the medication, and typically diminish significantly after the first 4 to 8 weeks of treatment. Shed's physicians manage this through gradual dose titration - starting at a low dose and incrementing slowly - which is consistent with FDA-recommended dosing protocols. The availability of multiple medication formats at Shed (injections, sublingual, lozenges, tablets) also provides additional tools for managing tolerability, as different delivery methods may produce different side effect profiles for individual patients.

Serious but rare side effects of GLP-1 medications include pancreatitis, gallbladder disease, and potential thyroid effects. The FDA requires a boxed warning on semaglutide products regarding the risk of thyroid C-cell tumors observed in rodent studies, although this risk has not been confirmed in humans. Shed's initial health screening is designed to identify patients with contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, who should not use GLP-1 medications.

One advantage of Shed's physician-supervised model is ongoing side effect management. Unlike direct-to-consumer medication purchases, Shed's subscription includes access to your prescribing physician for dose adjustments and clinical guidance throughout treatment. If you experience persistent nausea, your physician can slow the titration schedule, adjust the dose, or switch to a different GLP-1 format. This active management approach is consistent with best practices outlined by the American Gastroenterological Association for managing GLP-1 gastrointestinal effects.

Patients should also be aware that discontinuing GLP-1 medications typically leads to weight regain. Published studies show that patients regain approximately two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., 2022). This is not a Shed-specific limitation but a characteristic of the medication class, and it underscores the importance of discussing long-term treatment planning with your Shed physician rather than viewing GLP-1 therapy as a short-term solution.

As a telehealth provider handling protected health information (PHI), Shed is subject to the Health Insurance Portability and Accountability Act (HIPAA), which establishes national standards for protecting patient health data. HIPAA compliance requires administrative safeguards (workforce training, access controls), physical safeguards (facility security), and technical safeguards (encryption, audit controls) for all systems that process, store, or transmit PHI. Any telehealth platform operating in the United States must meet these baseline requirements.

Shed's online platform collects sensitive information including your medical history, current medications, weight data, and payment information. Under HIPAA's Security Rule, this data must be encrypted both in transit (when being transmitted between your device and Shed's servers) and at rest (when stored on their systems). The HHS Office for Civil Rights actively enforces HIPAA requirements and publishes a public breach portal where any significant data breaches affecting 500 or more individuals must be reported.

You can verify Shed's data protection practices by reviewing their privacy policy and terms of service, which should detail what information is collected, how it is used, who it is shared with, and what security measures are in place. Under HIPAA, you also have the right to request an accounting of disclosures - a record of who your health information has been shared with and why. Legitimate telehealth providers should honor these requests promptly and transparently.

For patients concerned about data privacy, practical steps include using a strong unique password for your Shed account, enabling two-factor authentication if available, and being cautious about accessing your account on public Wi-Fi networks. The National Institute of Standards and Technology (NIST) recommends these baseline cybersecurity practices for any online account containing sensitive information. Additionally, monitor your account for any unauthorized access and report suspicious activity immediately.

Shed's pharmacy partners are also independently subject to HIPAA requirements and state pharmacy board privacy regulations. The chain of custody for your prescription information - from Shed's platform to the prescribing physician to the dispensing pharmacy - must maintain HIPAA compliance at every step. This multi-layered regulatory oversight provides reasonable assurance that your health data is protected throughout the treatment process, though no system is immune to all security risks.

After thorough evaluation, Shed presents a compelling option in the telehealth GLP-1 weight loss market, distinguished primarily by its 10% weight loss money-back guarantee and its breadth of medication format options. The combination of over 150,000 members, 7,500-plus reviews averaging 4.6 out of 5 stars, and an outcome-based guarantee creates a credibility profile that exceeds many competitors in the space. The company's exclusive focus on GLP-1 weight loss - rather than spreading across multiple therapeutic areas - suggests operational depth and clinical specialization.

The pricing range of $199 to $499 per month is competitive within the telehealth GLP-1 market, particularly considering the all-inclusive nature of the subscription and the availability of both compounded and brand-name medications. For patients paying out of pocket, the lower-tier compounded options provide access to GLP-1 therapy at a fraction of the retail cost of brand-name alternatives. The 10% weight loss guarantee effectively reduces financial risk by tying the company's compensation to your clinical outcome - a structure that benefits patients regardless of whether the guarantee is ultimately exercised.

Shed's strongest differentiators are its medication format variety (injections, sublingual drops, lozenges, and oral tablets), its dual availability of compounded and brand-name GLP-1 options, and the outcome-based guarantee. These features address three of the most common barriers to GLP-1 treatment: needle aversion, medication supply disruptions, and financial uncertainty about whether the treatment will work. For patients who have hesitated to try GLP-1 therapy due to any of these concerns, Shed's model is specifically designed to lower those barriers.

Areas where potential patients should exercise due diligence include confirming the specific terms of the 10% weight loss guarantee before enrolling, understanding the cancellation process, and verifying that their prescribing physician holds appropriate licensure through the FSMB or state medical board databases. These verification steps are recommended for any telehealth service, not specific to concerns about Shed, and represent standard consumer protection practices in digital healthcare.

For individuals with a BMI of 30 or above (or 27-plus with weight-related comorbidities) who are considering GLP-1 therapy, Shed offers a well-structured, physician-supervised program with meaningful accountability mechanisms. The 10% weight loss guarantee, combined with the flexibility of multiple medication formats and the option to choose between compounded and brand-name formulations, makes Shed a strong contender for patients prioritizing both value and clinical outcome assurance. As with any medical treatment, the best results come from consistent adherence to the prescribed protocol and open communication with your care team.